October 15th 2025
Merck reveals promising phase 3 results for DOR/ISL, showing minimal impact on weight and lipids in adults with suppressed HIV-1.
IDWeek 2023: New Data Provide Closer Look at Real-World Utilization of Cabotegravir for HIV PrEP
October 15th 2023IDWeek 2023. New study found just slightly more than half of prescriptions for cabotegravir for HIV PrEP resulted in at least 1 injection, suggesting limitations in use and access to the injectable HIV integrase inhibitor.
HIV-1 Infection More Virulent in Heterosexual Persons, According to New Study
March 25th 2022New study suggests HIV-1 infection is more virulent when transmitted through heterosexual penile-vaginal intercourse than through anal intercourse between men who have sex with men due to transmission bottlenecks.